Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated May 30, 2016 (10 years ago)

Irbesartan and Hydrochlorothiazide Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or Exp Date: Incorrect lot number, 327B160012, appears on the case label, the correct lot number, 327B16002 appears on the immediate container.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Irbesartan and Hydrochlorothiazide Tablets, USP, 300/12.5 mg, Rx only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd, Xunqiao, Linhai, Zhejiang 317024, China; Distributed by: Solco Healthcare U.S., LLC, Cranbury, NJ 08512, NDC 43547-331-09.

Affected NDC 43547-0331-09

Compare with the code on your package — it is the most precise check available.

Drug: Hydrochlorothiazide Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Irbesartan and Hydrochlorothiazide
NDC 43547-0331
IRBESARTAN 300 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 Tablet
Oral
Solco Healthcare US, LLC Rx
Recalling firm
Prinston Pharmaceutical Inc
NDC code
43547-331-09
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1049-2016 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrochlorothiazide recalls

See all
Class II · Moderate risk

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Ongoing Labeling / mix-up Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025

Other recalls by Prinston Pharmaceutical Inc

All 2016 recalls
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-330-03 D-0413-2019
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-331-09 D-0412-2019
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-331-03 D-0411-2019
Class II · Moderate risk

Irbesartan and HydrochlorothiazideTablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-330-09 D-0410-2019